Evaxion's ai technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the evx-01 phase 1 clinical trial

Copenhagen, denmark, june 03, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-powered immunotherapies, today presented promising clinical data from its evx-01 phase 1 dose escalation trial in metastatic melanoma at the 2023 asco annual meeting in chicago, illinois.
EVAX Ratings Summary
EVAX Quant Ranking